Clinical Research Directory
Browse clinical research sites, groups, and studies.
3 clinical studies listed.
Filters:
Tundra lists 3 Mass Balance Study clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07906197
A Mass Balance Study on [14C]Levornidazole Disodium Phosphate for Injection in Healthy Chinese Adult Male Subjects
To quantitatively analyze the total radioactivity in excreta from healthy male subjects following a single intravenous infusion of \[14C\]levornidazole disodium phosphate, and to semi-quantitatively estimate the recovery of 14CO₂ in exhaled breath, thereby obtaining the human radioactivity recovery data and identifying the major routes of excretion; To analyze the radioactive metabolite profiles in human plasma, urine, and feces from healthy male subjects following a single intravenous infusion of \[14C\]levornidazole disodium phosphate, to identify the major metabolites, and to determine the metabolic pathways and elimination routes of levornidazole disodium phosphate in humans; To quantitatively analyze the total radioactivity in whole blood and plasma from healthy male subjects following a single intravenous infusion of \[14C\]levornidazole disodium phosphate, to obtain the pharmacokinetic parameters of total radioactivity in plasma, and to investigate the distribution of total radioactivity between whole blood and plasma.
Gender: MALE
Ages: 18 Years - 45 Years
Updated: 2026-10-30
NCT07644442
Study on [14C]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male Subjects
To evaluate the absorption, metabolism and excretion in healthy Chinese male subjects after a single oral dose of \[14C\]HMPL-453
Gender: MALE
Ages: 18 Years - 45 Years
Updated: 2026-06-12
1 state
NCT07411742
Mass Balance Study of [14C] D-2570
Radiolabeled drug substance balance clinical studies are commonly used methods to elucidate the metabolic and excretion characteristics of drugs in the human body. They are widely applied in the research and development of innovative drugs both domestically and internationally, and their safety has been validated through extensive human trials. The primary objectives of this study are as follows: To quantitatively analyze the total radioactive activity (TRA) in urine and feces, thereby determining the radioactive recovery rate in humans and identifying the primary excretion pathways. To obtain radioactive metabolite profiles in human plasma, urine, and feces, identify the major metabolites, and determine the principal metabolic and elimination pathways. To quantitatively analyze the total radioactive activity in whole blood and plasma, derive the pharmacokinetic parameters for total radioactivity in plasma and whole blood (if applicable), and investigate the distribution of total radioactivity between whole blood and plasma.
Gender: MALE
Ages: 18 Years - 45 Years
Updated: 2026-04-29
1 state